China Resources Pharmaceutical Group Limited (CHINARES PHARMA) filed its Monthly Return for Equity Issuer for the period ended 31 May 2026, confirming stable capital metrics and adherence to Hong Kong listing requirements.

Key highlights:

1. Issued Share Capital • Ordinary shares in issue (excluding treasury shares) stood unchanged at 6.28 billion. • The company held no treasury shares, leaving total issued share count likewise at 6.28 billion. • No new shares were issued, cancelled, or repurchased during the month.

2. Public Float • Management confirmed compliance with the Main Board’s minimum public-float threshold of 25% as at 31 May 2026.

3. Equity Incentives • The Share Option Scheme reported zero outstanding options; however, the mandate still allows up to 628.45 million shares to be issued upon future option grants and exercises. No options were exercised in May, and no funds were raised from option exercises.

4. Other Instruments and Movements • The filing recorded no warrants, convertibles, other share-issuance arrangements, or additional share movements.

The unchanged share base, absence of treasury stock, and verified public-float sufficiency underscore a stable capital structure for CHINARES PHARMA at the May 2026 month-end reporting date.